AI-CVD vs Merge PACS
AI Verdict
Choose AI-CVD if…
Choose AI-CVD if your primary objective is to opportunistically screen for cardiovascular and multisystem disease risks using existing CT scans, without requiring additional imaging, radiation, or workflow disruption. This tool is ideal for health systems aiming to proactively identify hidden health risks like coronary artery calcium or epicardial fat volumetry from routine chest and abdominal CTs, thereby enhancing preventative care and patient stratification.
View AI-CVD →Choose Merge PACS if…
Choose Merge PACS if your organization requires an enterprise-level solution for comprehensive imaging data management, streamlined diagnostic workflows, and robust integration of various AI applications across multiple specialties and sites. This system is best suited for health systems aiming to consolidate imaging data, optimize radiologist efficiency with customizable worklists and advanced diagnostic features, and establish a future-proof platform for AI-enhanced interpretation.
View Merge PACS →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AI-CVD | Merge PACS |
|---|---|---|
| Pricing | Unknown | Contact vendor |
| Deployment | Unknown | On-premise, Cloud, Hybrid |
| FDA Status | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Merge PACSMerge PACS, as a comprehensive PACS system, is designed for extensive workflow management and diagnostic interpretation, offering a customizable worklist and seamless integration of AI insights from various sources. While AI-CVD is easy to use for its specific, automated screening function by leveraging existing CT scans without workflow disruption, Merge PACS provides broader usability for daily clinical operations across an enterprise.
Clinical Value
AI-CVDAI-CVD offers direct, specific, and FDA-cleared clinical measurements and opportunistic screening for cardiovascular and multisystem diseases, providing concrete data points for early detection and risk stratification. Merge PACS, while crucial for workflow and data management, primarily facilitates diagnostic interpretation and the integration of other AI tools, rather than generating specific clinical insights itself.
Pricing & Value
TieBoth vendors require direct contact for pricing, preventing a quantitative comparison. Both offer significant value propositions: AI-CVD through opportunistic screening and early detection, and Merge PACS through workflow optimization and enterprise-wide imaging management and AI integration.
Enterprise Readiness
Merge PACSMerge PACS is explicitly designed as an 'enterprise-level' solution for 'multi-site health systems,' offering comprehensive integration capabilities with existing hospital IT infrastructure and flexible deployment options (on-premise, cloud, hybrid). AI-CVD is cloud-deployed and likely compliant, but its description doesn't emphasize enterprise-wide management or integration to the same extent as Merge PACS.
Innovation
AI-CVDAI-CVD is more innovative in its direct application of AI to generate novel, specific clinical insights from existing data for opportunistic screening and early disease detection, offering a new paradigm for preventive medicine. Merge PACS, while crucial for AI integration, primarily provides the platform and workflow for other AI innovations rather than being the source of the AI-driven clinical insight itself.
Support & Docs
Merge PACSMerative, the company behind Merge PACS, demonstrates more robust and transparent support and documentation resources, including a dedicated support portal, professional services, and detailed outlines for case handling and service level objectives. HeartLung Corporation provides contact information and a knowledge center, but lacks the explicit, structured support framework evident for Merge PACS.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AI-CVD | Merge PACS |
|---|---|---|
| Name | AI-CVD | Merge PACS |
| Company | HeartLung Corporation | Merative |
| Description | FDA-cleared, AI-powered quantitative imaging platform that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks. | Enterprise-level Picture Archiving and Communication System (PACS) that streamlines radiology workflows, consolidates imaging data, and integrates AI insights across multi-site health systems. It supports multi-modality diagnostic interpretation with flexible deployment options. |
| Key Features | Automated CT-derived anatomical and density-based measurements, Opportunistic screening from existing chest and abdominal CT scans, No additional imaging, radiation, contrast, or workflow disruption, Coronary Artery Calcium (CAC) scoring, Aortic wall, aortic valve, and mitral valve calcium analysis, Cardiac chamber volumetry (Left Atrium, Left Ventricle, Right Atrium, Right Ventricle), Epicardial fat volumetry, Aorta and pulmonary artery sizing | AI integration and readiness (single worklist access to 3rd party AI applications), Customizable, composite worklist for multiple specialties, Cloud-ready architecture (on-premise, cloud, hybrid deployment options), Enhanced diagnostic workflows (e.g., Synchronized Priors Scrolling for mammography, image fusion), Real-time analytics and dashboards (Merge Dashboards), Enterprise-wide image management and consolidation, Integration with EMR/EHR, RIS, HIS, and VNA systems, Secure web-based access for remote reading |
| Specialties | Cardiology, Pulmonology, Radiology | Cardiology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring AI-CVD and Merge PACS.